iBio Begins Phase 1 Clinical Trial for Obesity Drug Candidate IBIO-600

iBio has transitioned into a clinical-stage company following the administration of the first dose of IBIO-600 to a participant in a Phase 1 clinical trial. The study evaluates the safety and tolerability of the drug candidate in adults diagnosed with obesity.

Researchers designed this initial trial to assess how human subjects respond to the treatment, marking the company’s first move into clinical-stage testing. The study monitors participants for adverse reactions and physiological responses to determine the drug’s safety profile. This milestone follows the company’s previous preclinical development efforts and establishes a formal clinical pathway for the IBIO-600 program.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 2, 2026

Author

GOAI